Brokerages Set Altimmune, Inc. (NASDAQ:ALT) PT at $18.80

Altimmune, Inc. (NASDAQ:ALT) has earned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $18.80.

Several research analysts have recently commented on ALT shares. B. Riley reissued a “buy” rating and issued a $20.00 target price on shares of Altimmune in a report on Tuesday. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Altimmune in a report on Tuesday, May 14th. JMP Securities cut their price target on Altimmune from $25.00 to $24.00 and set a “market outperform” rating for the company in a report on Friday, May 10th. Piper Sandler reissued an “overweight” rating and set a $25.00 price objective on shares of Altimmune in a report on Friday, June 21st. Finally, Guggenheim downgraded shares of Altimmune from a “buy” rating to a “neutral” rating in a research note on Monday, April 29th.

Institutional Trading of Altimmune

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Timelo Investment Management Inc. raised its stake in shares of Altimmune by 2,597.0% during the fourth quarter. Timelo Investment Management Inc. now owns 809,095 shares of the company’s stock worth $9,102,000 after buying an additional 779,095 shares during the last quarter. Farallon Capital Management LLC raised its position in shares of Altimmune by 1,282.4% during the 1st quarter. Farallon Capital Management LLC now owns 470,000 shares of the company’s stock valued at $4,785,000 after acquiring an additional 436,000 shares during the last quarter. Lighthouse Investment Partners LLC bought a new stake in shares of Altimmune during the 4th quarter valued at $4,493,000. Knoll Capital Management LLC lifted its stake in shares of Altimmune by 183.6% in the 1st quarter. Knoll Capital Management LLC now owns 567,219 shares of the company’s stock valued at $5,774,000 after purchasing an additional 367,219 shares during the period. Finally, GSA Capital Partners LLP boosted its position in shares of Altimmune by 153.1% in the 3rd quarter. GSA Capital Partners LLP now owns 445,868 shares of the company’s stock worth $1,159,000 after purchasing an additional 269,676 shares during the last quarter. 78.05% of the stock is owned by institutional investors.

Altimmune Price Performance

Shares of NASDAQ:ALT opened at $6.39 on Friday. The stock has a market capitalization of $452.71 million, a price-to-earnings ratio of -4.02 and a beta of 0.11. The business’s fifty day moving average price is $7.08 and its two-hundred day moving average price is $8.77. Altimmune has a fifty-two week low of $2.09 and a fifty-two week high of $14.84.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.02. The firm had revenue of $0.01 million during the quarter. Altimmune had a negative net margin of 22,645.37% and a negative return on equity of 46.96%. During the same period in the prior year, the business earned ($0.40) earnings per share. Research analysts expect that Altimmune will post -1.34 EPS for the current fiscal year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.